Wedbush Securities Inc Aquestive Therapeutics, Inc. Transaction History

Wedbush Securities Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 08, 2021	SELL	$3.25 - $4.66 $34,125 - $48,930	-10,500 Closed	0 $0
Q2 2021 Jul 27, 2021	BUY	$3.29 - $5.21 $1,645 - $2,605	500 Added 5.0%	10,500 $41,000
Q1 2021 Apr 26, 2021	BUY	$4.17 - $6.73 $41,700 - $67,300	10,000 New	10,000 $52,000
Q4 2020 Feb 16, 2021	SELL	$4.65 - $7.79 $480,066 - $804,239	-103,240 Closed	0 $0
Q3 2020 Oct 20, 2020	SELL	$4.12 - $9.09 $138,773 - $306,178	-33,683 Reduced 24.6%	103,240 $501,000
Q2 2020 Jul 16, 2020	BUY	$1.84 - $6.44 $92,288 - $323,011	50,157 Added 57.81%	136,923 $665,000
Q1 2020 Apr 17, 2020	BUY	$1.54 - $6.75 $37,471 - $164,241	24,332 Added 38.97%	86,766 $190,000
Q4 2019 Jan 16, 2020	SELL	$3.06 - $8.78 $110,328 - $316,562	-36,055 Reduced 36.61%	62,434 $363,000
Q3 2019 Oct 17, 2019	BUY	$3.04 - $4.91 $84,378 - $136,281	27,756 Added 39.24%	98,489 $313,000
Q2 2019 Aug 01, 2019	BUY	$3.72 - $6.95 $263,126 - $491,594	70,733 New	70,733 $297,000

121

46.7M

517K

207K

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $163M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.